Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

Abstract

Worldwide, the incidence of primary brain tumors is on the rise. Unfortunately, noninvasive drug therapy is hampered by poor access of most drugs to the brain due to the insurmountable blood-brain barrier (BBB). Nanotechnology holds great promise for noninvasive therapy of severe brain diseases. Furthermore, recent bioconjugation strategies have enabled the invasion of the BBB via tailored-designed bioconjugates either with targeting moieties or alterations in the physicochemical and/or the pharmacokinetic parameters of central nervous system (CNS) active pharmaceutical ingredients. Multifunctional systems and new entities are being developed to target brain cells and tumor cells to resist the progression of brain tumors. Direct conjugation of an FDA-approved drug with a targeting moiety, diagnostic moiety, or pharmacokinetic-modifying moiety represents another current approach in combating brain tumors and metastases. Finally, genetic engineering, stem cells, and vaccinations are innovative nontraditional approaches described in different patents for the management of brain tumors and metastases. This review summarizes the recent technologies and patent applications in the past five years for the noninvasive treatment of glioblastoma and other brain tumors. Till now, there has been no optimal strategy to deliver therapeutic agents to the CNS for the treatment of brain tumors and metastases. Intensive research efforts are ongoing to bring novel CNS delivery systems to potential clinical application.

Keywords

Glioblastoma / brain delivery / blood-brain barrier / nanotechnology / novel treatment

References

[1] Jex HSThe Edwin Smith Surgical Papyrus: first milestone in the march of medicine..Merck Rep1951;60:20-2

[2] Sanchez GMThe Edwin Smith Papyrus: Updated translation of the trauma treatise and modern medical commentaries: Lockwood Press;2012;

[3] Brayn CPThe Papyrus Ebers, translated from the german version..Letchworth, Herts. The Guardian City Press LTD;1930;

[4] Papavramidou NDemetriou TAncient Greek and Greco-Roman methods in modern surgical treatment of cancer..Ann Surg Oncol2010;17:665-7PMC2820670

[5] Ferlay J SIDikshit RMathers CParkin DMBray FGlobocan 2012, Cancer Incidence and Mortality Worldwide: IARC..In: internet N, editor. Cancer Fact Sheets.Lyon, FranceInternational Agency for Research on Cancer2013;

[6] Dolecek TAStroup NECBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009..Neuro Oncol2012;14 Suppl 5:v1-49

[7] Ostrom QTFarah PChen YStroup NEBarnholtz-Sloan JSCBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010..Neuro Oncol2013;15 Suppl 2:ii1-56

[8] Molnár PtClassification of primary brain tumors: molecular aspects, management of CNS tumors..InTech;2011;

[9] Chandana SRArora MPrimary brain tumors in adults..Am Fam Physician2008;77:1423-30

[10] Parrish KEElmquist WFImproving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier..Clin Pharmacol Ther2015;97:336-46

[11] Alifieris CGlioblastoma multiforme: Pathogenesis and treatment..Pharmacol Ther2015;152:63-82

[12] Armstrong TSHead's up on the treatment of malignant glioma patients..Oncol Nurs Forum2009;36:E232-40

[13] Wen PYMalignant Gliomas in Adults..N Engl J Med2008;359:492-507

[14] Kleihues PPrimary and secondary glioblastomas: from concept to clinical diagnosis..Neuro Oncol1999;1:44-51PMC1919466

[15] Ballabh PNedergaard MThe blood-brain barrier: an overview: structure, regulation, and clinical implications..Neurobiol Dis2004;16:1-13

[16] Cook LJBrain Tumors..New YorkThe Rosen Publishing Group2012;

[17] Dauchy SCouraud POWeksler BScherrmann JMDecleves XExpression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells..Biochem Pharmacol2009;77:897-909

[18] Abbott NJOverview and introduction: the blood-brain barrier in health and disease..Epilepsia2012;53:1-6PMC3625728

[19] van Tellingen Ode Gooijer MCWurdinger TOvercoming the blood-brain tumor barrier for effective glioblastoma treatment..Drug Resist Updat2015;19:1-12

[20] Hawkins BTThe blood-brain barrier/neurovascular unit in health and disease..Pharmacol Rev2005;57:173-85

[21] Deeken JFThe blood-brain barrier and cancer: transporters, treatment, and Trojan horses..Clin Cancer Res2007;13:1663-74

[22] Barthomeuf CBayet-Robert MCurcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis..In: Institut National De La Sante Et De La Recherche Medicale (Inserm);2014;(ISBN No. US20140128337 A1)

[23] Loscher WBlood-brain barrier active efflux transporters: ATP-binding cassette gene family..NeuroRx2005;2:86-98PMC539326

[24] Ghosh CHossain MFazio VMarchi NPattern of P450 expression at the human blood-brain barrier: Roles of epileptic condition and laminar flow..Epilepsia2010;51:1408-17PMC3386640

[25] Minn APerrin RSiest GDrug metabolizing enzymes in the brain and cerebral microvessels..Brain Res Brain Res Rev1991;16:65-82

[26] Dhermain FGLanfermann Hvan den Bent MJAdvanced MRI and PET imaging for assessment of treatment response in patients with gliomas..Lancet Neurol2010;9:906-20

[27] Tzeng SYTherapeutic nanomedicine for brain cancer..Ther Deliv2013;4:10.4155/tde.13.38

[28] Madsen SJSite-specific opening of the blood-brain barrier..J Biophotonics2010;3:356-67PMC4116190

[29] Kazantsev AGDrug discovery for CNS disorders: from bench to bedside..CNS Neurol Disord Drug Targets2010;9:668

[30] Gabathuler RApproaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases..Neurobiol Dis2010;37:48-57

[31] Pardridge WMDrug delivery to the brain..J Cereb Blood Flow Metab1997;17:713-31

[32] Drappatz JWong ETSchiff DMikkelsen TSarantopoulos JFielding RMWang XShing MCastaigne JPPhase I Study of GRN1005 in Recurrent Malignant Glioma..Clin Cancer Res2013;19:1567-76

[33] Jones ARBlood-brain barrier transport of therapeutics via receptor-mediation..Pharm Res2007;24:1759-71PMC2685177

[34] Rip Jde Boer AGDifferential receptor-mediated drug targeting to the diseased brain..Expert Opin Drug Deliv2009;6:227-37

[35] Wang YYLi JYReceptor-mediated therapeutic transport across the blood-brain barrier..Immunotherapy2009;1:983-93

[36] Papademetriou LTPromising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer..Ther Deliv2015;6:989-1016PMC4618388

[37] Demeule MChe CNguyen TCastaigne JPIdentification and design of peptides as a new drug delivery system for the brain..J Pharmacol Exp Ther2008;324:1064-72

[38] Jefferies WCNS-targeted conjugates having modified fc regions and methods of use thereof..In: Bioasis Technologies Inc.;2015;(ISBN No. US20150093399 A1)

[39] Demeule MBertrand YNguyen TGabathuler RBeliveau RInvolvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2..J Neurochem2008;106:1534-44

[40] Kurzrock RChandhasin CSmith CSankhala KElian KSarantopoulos JSafety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors..Mol Cancer Ther2012;11:308-16

[41] Menlo Park CGeron Discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres..In; 2012

[42] Che CThiot CCurrie JCRegina ACastaigne JPNew Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration..J Med Chem2010;53:2814-24

[43] Bertrand YDemeule MChe CFatehi DGabathuler RStanimirovic DTransport characteristics of a novel peptide platform for CNS therapeutics..J Cell Mol Med2010;14:2827-39PMC3822732

[44] Thomas FCRudraraju VThorsheim HRMittapalli RKSteeg PSSmith QRUptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer..Pharm Res2009;26:2486-94PMC2896053

[45] Xin HGu JChen LChen YJiang YAngiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma..Biomaterials2011;32:4293-305

[46] Shen JXie CGu BZhang YPoly (ethylene glycol)-block-poly(D, L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery..J Drug Target2011;19:197-203

[47] Sun XYe HGuo LRen JZhang QJiang XCo-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome..Biomaterials2012;33:916-24

[48] Gaillard PJConjugates for targeted drug delivery across the blood-brain barrier..In: to-BBB Holding B.V.; 2013(ISBN No. EP2308514 B1)

[49] Gaillard PJBrink ADifferentially Expressed Nucleic Acids in the Blood–Brain Barrier Under Inflammatory Conditions..In: Gaillard, P.J.De Boer, A.G. Brink, A.; 2008(ISBN No. US20080213179 A1)

[50] Gaillard PJGlutathione-based drug delivery system.In: To-Bbb Holding B.V.; 2010(ISBN No. WO2010095940 A2)

[51] Dickerson IMMethods of treating cancer using an agent that modulates activity of the calcitonin-gene related peptide ("CGRP") receptor..In: University Of Rochester; 2011(ISBN No. US 20110189205 A1)

[52] Furness SWookey PJDiagnosis and treatment of brain tumors..In: Welcome Receptor Antibodies Pty Ltd; 2012(ISBN No. WO2012000062 A1)

[53] Tortorella STransferrin receptor-mediated endocytosis: a useful target for cancer therapy..J Membr Biol2014;247:291-307

[54] Ding HHoller EPoly (beta malic acid) with pendant Leu-Leu-Leu tripeptide for effective cytoplasmic drug delivery..In: Cedars-Sinai Medical Center; 2014(ISBN No. US 8795648 B2)

[55] Patil RBlack KLDrug delivery of temozolomide for systemic based treatment of cancer..In: Cedars-Sinai Medical Center; 2014(ISBN No. US20140161762 A1)

[56] Weiss NCazaubon S[Blood–brain barrier part III: therapeutic approaches to cross the blood–brain barrier and target the brain]..Rev Neurol2010;166:284-8

[57] Estella-Hermoso de Mendoza AMollinedo FIn vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma..J Control Release2011;156:421-6

[58] Coley HMOvercoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors..Methods Mol Biol2010;596:341-58

[59] Das MFolate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance..PLoS One2012;7:e32920

[60] Kim MKChong YWater-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance..J Med Chem2014;57:7216-33

[61] Kim MKChoo HQuercetin-POM (pivaloxymethyl) conjugates: Modulatory activity for P-glycoprotein-based multidrug resistance..Phytomedicine2015;22:778-85

[62] Romiti NDonati AEffects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2..Life Sci2004;76:293-302

[63] Banks WADarling TModulation of blood-brain barrier protein expression..In: St. Louis University; 2010(ISBN No. US20100196393 A1)

[64] McChesney JDEmerson DLAhmed TKurman MTaxane analogs for the treatment of brain cancer..In: Tapestry Pharmaceuticals, Inc.; 2011(ISBN No. US 20110318334 A1)

[65] Tosi GRuozi BBadiali LCostantino LVandelli MASialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution..J Control Release2010;145:49-57

[66] Bazile DBassoullet MTSpenlehauer GStealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system..J Pharm Sci1995;84:493-8

[67] Niidome TOkamoto YTakahashi HKatayama YPEG-modified gold nanorods with a stealth character for in vivo applications..J Control Release2006;114:343-7

[68] Weissenbock AGabor FWGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells..J Control Release2004;99:383-92

[69] Brigger ICouvreur PNanoparticles in cancer therapy and diagnosis..Adv Drug Deliv Rev2002;54:631-51

[70] Zhang PSun JYuan YWang ZMultifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux..Biomaterials2011;32:5524-33

[71] Petkar KCAgatonovik-Kustrin SNanostructured materials in drug and gene delivery: a review of the state of the art..Crit Rev Ther Drug Carrier Syst2011;28:101-64

[72] Meyers JDBurda CNanoparticles for imaging and treating brain cancer..Nanomedicine2013;8:123-43PMC3564670

[73] Chen YModern methods for delivery of drugs across the blood-brain barrier..Adv Drug Deliv Rev2012;64:640-65

[74] De Jong WHDrug delivery and nanoparticles: applications and hazards..Int J Nanomedicine2008;3:133PMC2527668

[75] Garcia-Garcia EGil SColloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?.Int J Pharm2005;298:274-92

[76] Wesselinova DCurrent major cancer targets for nanoparticle systems..Curr Cancer Drug Targets2011;11:164-83

[77] Adams MLKwon GSAmphiphilic block copolymers for drug delivery..J Pharm Sci2003;92:1343-55

[78] Li AJLiu GDCao PCEfficient delivery of docetaxel for the treatment of brain tumors by cyclic RGD-tagged polymeric micelles..Mol Med Rep2015;11:3078-86

[79] Krebs MDBiodegradable polymers for delivery of therapeutic agents..In: Colorado School Of Mines; 2014(ISBN No. US20140377366 A1)

[80] Bae YHLee ESPH-sensitive polymeric micelles for drug delivery..In: University Of Utah Research Foundation; 2010(ISBN No. US 7659314 B2)

[81] Zhou ZPiepmeier JMHighly penetrative nanocarriers for treatment of cns disease..In: Yale University; 2015(ISBN No. US20150118311 A1)

[82] Wu XYPolymeric nanoparticles useful in theranostics..In: The Governing Council Of The University Of Toronto; 2013(ISBN No. WO2013127004 A1)

[83] Yerushalmi NLithwick YGOfek PNanocarrier system for micrornas and uses thereof..In: Rosetta Genomics Ltd. and Ramot At Tel-Aviv University Ltd; 2014(ISBN No. WO2014203189 A1)

[84] Tour JMMarcano DSharpe MATargeted nanovectors and their use for treatment of brain tumors..In: The Methodist Hospital Research Institute & William Marsh Rice University; 2014(ISBN No. US 20140154269 A1)

[85] Muller LKNatural liposomes and synthetic polymeric structures for biomedical applications..Biochem Biophys Res Commun2015;468:411-8

[86] Lai FSinico CLiposomes for brain delivery..Expert Opinion on Drug Delivery2013;10:1003-22

[87] Xiang YWang XZhang XChloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes..J Control Release2011;152:402-10

[88] Li XYSun MGJu RJLi XTMu LMLou JNMultifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma..Biomaterials2014;35:5591-604

[89] Chen HZhang QTang LHe QLactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas..Eur J Pharm Sci2011;44:164-73

[90] Migliore MMCampbell RBWaszczak BLBrain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations..J Pharm Sci2010;99:1745-61

[91] Munson JMArbiser JLNanocarrier therapy for treating invasive tumors..In: Emory University & Georgia Institute Of Technology; 2010(ISBN No. WO2010124004 A2)

[92] Redelmeier TLiposomal Composition for Convection-Enhanced Delivery to the Central Nervous system..In: MedGenesis Therapeutix Inc.; 2011(ISBN No. US20110274625 A1)

[93] Mehnert WSolid lipid nanoparticles: production, characterization and applications..Adv Drug Deliv Rev2001;47:165-96

[94] Kaur IPBhandari SPotential of solid lipid nanoparticles in brain targeting..J Control Release2008;127:97-109

[95] Panyam JLipid-derived nanoparticles for brain-targeted drug delivery..In: Panyam, J. and Chavanpatil, M. D.; 2010(ISBN No. US 20100076092 A1)

[96] Jin JYang HKim HJoo KMPark TGIn vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles..Bioconjug Chem2011;22:2568-72

[97] Singh IPooja DKhan WLactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting..J Drug Target2016;24:212-23

[98] Minotti GSalvatorelli EGianni LAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity..Pharmacol Rev2004;56:185-229

[99] Gaillard PJDorland RManca FWindhorst Bde Vries HEvan Tellingen OPharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)..PLoS One2014;9:e82331

[100] Gaillard PJAftimos PJager ALonnqvist FVerheul HSchellens JAbstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma..Cancer Res2014;74:CT216

[101] Nektar TherapeuticsEtirinotecan Pegol (NKTR-102): A Next-Generation Topoisomerase I Inhibitor Being Developed in Breast, Ovarian and Colorectal Cancers..In. Etirinotecan Pegol (NKTR-102). USA: "Nektar Therapeutics"; 2013

[102] Nagpal SBertrand SAjlan AGershon MKunz PLRecht LDPhase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma..Neuro Oncol2015;123:277-82PMC4452613

[103] Hermanson GTChapter 1 - Introduction to Bioconjugation. In: editor~editors, editor. Bioconjugate Techniques. Boston:Academic Press2013;1-125

[104] Duncan RPolymer conjugates as anticancer nanomedicines..Nat Rev Cancer2006;6:688-701

[105] Bacha JADunn SUse of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme..In: Del Mar Pharmaceuticals; 2014(ISBN No. US20140221442 A1)

[106] Tschoepe MKumar VAnti-egfr antibody drug conjugate formulations..In: Abbvie Deutschland Gmbh & Co.Kg, Abbvie Inc.; 2014(ISBN No. WO2014143765 A1)

[107] Adair JHSmith JPBarth BMMatters GLMorgan TTBioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo..In: The Pennsylvania State Research Foundation; 2011(ISBN No. WO 2011057216 A1)

[108] Hutchison RGabathuler RP97-antibody conjugates and methods of use..In: Bioasis Technologies, Inc.; 2013(ISBN No. US 20130183368 A1)

[109] Kang TJiang DYao JChen HChen JEnhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex..Mol Pharm2015;12:2947-61

[110] Dardevet LAziz TASabatier JMBrambilla EChlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion..Toxins (Basel).2015;7:1079-101PMC4417956

[111] Pyrko PMarkland FSSchmitmeier SChen TCThe role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model..J Neurosurg2005;103:526-37

[112] Kasai TVaidyanath ASekhar SOkada MKudoh TSeno MChlorotoxin Fused to IgG-Fc Inhibits Glioblastoma Cell Motility via Receptor-Mediated Endocytosis..J Drug Deliv2012;2012:975763PMC3523153

[113] Yoo BGhosh SMoore ACombination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ..Mol Imaging Biol2014;16:680-9

[114] Locatelli EUboldi CFragogeorgi EPucci APsimadas DFranchini MCTargeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma..Nanomedicine (Lond).2014;9:839-49

[115] Zhao LCheng YTang YShi XChlorotoxin-Conjugated Multifunctional Dendrimers Labeled with Radionuclide 131I for Single Photon Emission Computed Tomography Imaging and Radiotherapy of Gliomas..ACS Appl Mater Interfaces2015;7:19798-808

[116] Zhao LZhao JChlorotoxin-conjugated nanoparticles for targeted imaging and therapy of glioma..Curr Top Med Chem2015;15:1196-208

[117] Wang XChlorotoxin-conjugated onconase as a potential anti-glioma drug..Oncol Lett2015;9:1337-42PMC4315000

[118] Wang HXiao NXu QChlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug..Int J Nanomedicine2014;9:1433-42

[119] Cheng YQiao WRecent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates..Am J Nucl Med Mol Imaging2014;4:385-405

[120] Zhang MKievit FStephen ZNanoparticle for targeting brain tumors and delivery of o6-benzylguanine..In: University of Washington through its Center for Commercialization; 2014(ISBN No. US20140286872 A1)

[121] Veiseh OFang CJana SMok HPark JOChlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery..Biomaterials2010;31:8032-42PMC2930137

[122] Kievit FMFang CLee DZhang MChlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma..ACS Nano2010;4:4587-94PMC2928580

[123] Butte PVParrish-Novak JShweikeh FChesnokova ABlack KNear-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors..Neurosurg Focus2014;36:E1

[124] Fidel JDernell WSWiss VMolho JIMeganck JRice BPreclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors..Cancer Res2015;75:4283-91PMC4610180

[125] Rodriguez-Devora JIShi Z-DSun WPhysically facilitating drug-delivery systems..Ther Deliv2012;3:125-39PMC3319129

[126] Davalos RVGarcia PAAcute blood-brain barrier disruption using electrical energy based therapy..In: Virginia Tech Intellectual Properties, Inc.; 2014(ISBN No. US20140039489A1)

[127] Qiu LBLi KCZhou YLi YRThe role of protein kinase C in the opening of blood-brain barrier induced by electromagnetic pulse..Toxicology2010;273:29-34

[128] Braun SMueller AHovhannisyan AGebhardt RThiery JGaunitz FHedgehog signaling in glioblastoma multiforme..Cancer Biol Ther2012;13:487-95

[129] Akhtari MUse of functionalized magnetic nanoparticles in cancer detection and treatment.In: The Regents Of The University Of California; 2015. (ISBN No. US 9011913 B2)

[130] Yang VCCompositions and methods for targeting tumors.In: The Regents Of The University Of Michigan; 2011. (ISBN No. US20110054236 A1)

[131] Dixit SZhu YNovak TBroome AMDual Receptor-Targeted Theranostic Nanoparticles for Localized Delivery and Activation of Photodynamic Therapy Drug in Glioblastomas..Mol Pharm2015;12:3250-60PMC4564323

[132] Liu H-LTing C-YCombining Microbubbles and Ultrasound for Drug Delivery to Brain Tumors: Current Progress and Overview..Theranostics2014;4:432-44PMC3936295

[133] Hynynen KSheikov NAVykhodtseva NLocal and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications..Neuroimage2005;24:12-20

[134] Blomley MJKUnger ECCosgrove DOMicrobubble contrast agents: a new era in ultrasound..BMJ : British Medical Journal2001;322:1222-5PMC1120332

[135] Kang STUltrasound microbubble contrast agents for diagnostic and therapeutic applications: current status and future design..Chang Gung Med J2012;35:125-39

[136] Chen YCWu SKHsieh WYTargeting microbubbles-carrying TGFbeta1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors..J Control Release2015;211:53-62

[137] Liao AHHsieh YLWei KCEnhanced Therapeutic Epidermal Growth Factor Receptor (EGFR) Antibody Delivery via Pulsed Ultrasound with Targeting Microbubbles for Glioma Treatment..Journal of Medical and Biological Engineering2015;35:156-64PMC4414932

[138] Bartel DPMicroRNAs: genomics, biogenesis, mechanism, and function..Cell2004;116:281-97

[139] Iwakawa HOThe Functions of MicroRNAs: mRNA Decay and Translational Repression..Trends Cell Biol2015;

[140] Alvarez-Garcia IMicroRNA functions in animal development and human disease..Development2005;132:4653-62

[141] LeBlanc VCExploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients..J Clin Med2015;4:1612-30PMC4555080

[142] Hummel RHaier JMicroRNAs in brain tumors : a new diagnostic and therapeutic perspective?.Mol Neurobiol2011;44:223-34

[143] Novakova JVyzula RMicroRNA involvement in glioblastoma pathogenesis..Biochem Biophys Res Commun2009;386:1-5

[144] Chan JAKosik KSMicroRNA-21 is an antiapoptotic factor in human glioblastoma cells..Cancer Res2005;65:6029-33

[145] Møller HGAndersen HHHenriksen MA Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-modulators in the Mesenchymal Mode of Migration and Invasion..Molecular Neurobiology2013;47:131-44PMC3538124

[146] Park JBPark EKYang HSKim HJKwak HJAnti-cancer composition comprising microrna molecules..In: National Cancer Center; 2011(ISBN No. US20110124712 A1)

[147] Keefe ADEllington AAptamers as therapeutics..Nat Rev Drug Discov2010;9:537-50

[148] Rich JNHjelmeland AAptamers for tumor initiating cells..In: The Cleveland Clinic Foundation; 2014(ISBN No. WO2014121256 A1)

[149] Bloembergen SJones NShermon AKGLiu JAptamer bioconjugate drug delivery device..In: Ecosynthetix Ltd.; 2013(ISBN No. US 20130090467 A1)

[150] Jatariu APopa MMicro- and nanoparticles--medical applications..Rev Med Chir Soc Med Nat Iasi2009;113:1160-9

[151] Burgess RMedical applications of nanoparticles and nanomaterials..Stud Health Technol Inform2009;149:257-83

[152] Irache JM[Nanomedicine: nanoparticles with medical applications]..An Sist Sanit Navar2008;31:7-10

[153] Dusinska MFjellsbo LRinna ABartonova AHarju MRoss BHalamoda Kenzaui BBoland SSaunders MCarreira SKelin CPalosaari THousiadas CVolkovova KKazimirova ASebekova KKovacikova ZPoulsen MVila MFernandez BMarcomini ABilanicova DTesting strategies for the safety of nanoparticles used in medical applications..Nanomedicine2009;4:605-7

[154] to-BBB technologies BVCompany restarting as 2-BBB Medicines BV..In. The Netherlands;2015;

[155] TEDxMaastrichtBrain Train.Effective Brain Cancer Treatment: Pieter Gaillard at TEDxMaastricht. In: TEDxMaastricht, editor: Gaillard, P.; 2013

[156] Lammers TStorm GTumour-targeted nanomedicines: principles and practice..Br J Cancer2008;99:392-7PMC2527811